Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan PET/CT
NCT06222489Phase 2Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Mar 2025
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of patritumab deruxtecan in non-small cell lung carcinoma (NSCLC), sponsored by Netherlands Cancer Institute. Started Mar 2025; status: recruiting.
02
Drugs
patritumab deruxtecan
03
Conditions
non-small cell lung carcinoma (NSCLC)
Beyond the preview
Go deeper on NCT06222489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06222489.